Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AAR

- PMLiVE

Pharma frustration mounts as Johnson toys with no-deal Brexit pronouncements

No new government funds committed to no-deal medicines plans

- PMLiVE

England to fast-track tumour agnostic drugs like Vitrakvi – if the price is right

Simon Stevens calls for 'fair prices' from companies

- PMLiVE

Threat of no-deal damaging life sciences, says UK biotech leader

Calls for better-informed debate among Conservative candidates

- PMLiVE

Johnson retains lead after second Tory leadership vote

Meets business leaders to reassure on no-deal Brexit

- PMLiVE

Trump backtracks on ‘NHS on the table’ comments

Echoes mixed message at home about healthcare

- PMLiVE

Has Amgen cracked KRAS? First clinical data says maybe

Progess on cancer 'master switch'

- PMLiVE

Encouraging early data for Amgen’s BiTE therapies

Including first-in-man data from prostate cancer drug

- PMLiVE

Hancock says “NHS not for sale” in post-Brexit US trade talks

Tensions rise as President Trump arrives for state visit

- PMLiVE

UK pharma’s hard-to-recruit posts need foreign recruitment boost

Post-Brexit immigration policy still unclear

- PMLiVE

Deal or no deal? Brexit battlelines drawn in Tory leadership bids

Pharma industry warns again on no-deal impact

- PMLiVE

NHS England wants money-back guarantee on Orkambi

Vertex resisting real-world data proposal

- PMLiVE

Still no breakthrough on Orkambi talks, MPs want answers

As other price deals go through, Orkambi stalled again

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links